Three cases of an SGLT-2 inhibitor prescribed in combination with a GLP-1 agonist have been described in PWS, with marked improvement in HbA1c and significant weight loss following initiation of treatment [37,38,46]. The gene discussed is SLC5A2; the disease is Prader-Willi syndrome.